WASP, N-, Control Peptide (WAS, THC, IMD2, WASP, Eczema-thrombocytopenia)

Catalog Number: USB-W0800-02
Article Name: WASP, N-, Control Peptide (WAS, THC, IMD2, WASP, Eczema-thrombocytopenia)
Biozol Catalog Number: USB-W0800-02
Supplier Catalog Number: W0800-02
Alternative Catalog Number: USB-W0800-02-50
Manufacturer: US Biological
Category: Molekularbiologie
Application: ELISA
The Wiskott-Aldrich syndrome (WAS) family of proteins share similar domain structure, and are involved in transduction of signals from receptors on the cell surface to the actin cytoskeleton. The presence of a number of different motifs suggests that they are regulated by a number of different stimuli, and interact with multiple proteins. Recent studies have demonstrated that these proteins, directly or indirectly, associate with the small GTPase, Cdc42, known to regulate formation of actin filaments, and the cytoskeletal organizing complex, Arp2/3, which can nucleate actin polymerization at sites that lead to branched actin structures. These proteins have 48% identity in human with the highest homology in the functional regions of these proteins. Serine and tyrosine phosphorylation regulates the activity of both proteins. WASP is observed as a 63kD protein in hematopoietic cells, while N-WASP is observed as a 65kD in many tissues, especially brain. Wiskott-Aldrich syndrome is a rare, inherited, X-linked, recessive disease characterized by immune dysregulation and microthrombocytopenia, and is caused by mutations in the WAS gene. The WAS gene product is a cytoplasmic protein, expressed exclusively in hematopoietic cells, which show signalling and cytoskeletal abnormalities in WAS patients. These clinical findings as well as the structural properties of WASP (including a cdc42 binding site, SH3 domain binding region and regions for actin cytoskeletal localization) suggest a pivotal role for WASP in regulating the structure and function of platelets and T-lymphocytes. A transcript variant arising as a result of alternative promoter usage, and containing a different 5 UTR sequence, has been described, however, its full-length nature is not known. Applications: Suitable for use in ELISA or for antigen applications in immunological protocols. Other applications not tested. Recommended Dilution: End user should determine optimal dilution for their particular applications and experiments. These peptides quantities were established in 96-well plates where the peptide was bound to plates for 2 hrs in 0.1M sodium carbonate buffer, pH 8.5. Storage and Stability: May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 6 months after receipt at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Purity: Purified
Form: Supplied as a liquid in PBS with 0.05% sodium azide.